Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients
Study Details
Study Description
Brief Summary
The purpose of this trial is to compare the difference in the proportion of patients with tolerable pain scores, VAS pain scores, quality of recovery and opioid use in milligram equivalents (at 24, 48, 72, 96 and 120 hours postoperatively) in patients undergoing shoulder arthroplasty who receive interscalene blocks with or without Liposomal Bupivacaine.
This is a prospective randomized, double-blinded, controlled trial that will enroll 120 subjects undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty. Participants who meet all eligibility criteria will be randomized in a 1:1 ratio to receive either 36 mL of 0.5% bupivacaine (PB group) or 10 mL of liposomal bupivacaine and 20 mL of 0.25 % bupivacaine and 6 mL of saline (LB group).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Patients undergoing shoulder surgery can suffer from significant postoperative pain which can lead to an increase in recovery time, opioid use and potential dependency, and a decrease in quality of recovery. The interscalene brachial plexus block is a common effective regional anesthesia technique used for a variety of procedures involving the shoulder. The number of total shoulder arthroplasty surgeries being performed annually in the United States are increasing every year. Liposomal bupivacaine was FDA approved for use in patients undergoing interscalene block in 2018 to reduce postoperative pain from shoulder surgery. The information from the manufacturer indicates that the liposomal encapsulation may release the drug for up to approximately 72 hours after it has been administered, providing a prolonged analgesic effect. Evidence to the prolonged analgesic effect of liposomal bupivacaine has varied in the current literature. A recent meta-analysis suggested that liposomal bupivacaine may provide a statistically significant, but clinically insignificant decrease in opioid consumption and pain scores over time. The authors noted a possible limitation of their study is that the meta-analysis included a variety of surgical procedures and block techniques, and was not specific to shoulder surgery or interscalene block. The authors noted that this variability in anesthetic regimens between study groups could have affected the observed outcomes.
Recently, the investigators performed a retrospective quality improvement study to investigate the potential benefit of liposomal bupivacaine used for interscalene blocks among 491 patients undergoing shoulder arthroplasty between 2018 and 2021. The investigators compared the difference in the proportion of patients with clinically tolerable pain scores (defined as VAS ≤ 4) in those patients receiving liposomal bupivacaine vs. those receiving another local anesthetic (plain bupivacaine, mepivacaine or ropivacaine) vs. those receiving no block. The results of this study suggested there was significant difference in the proportion of patients with clinically tolerable pain scores when receiving liposomal bupivacaine during all observations and at 3 days postoperatively versus those patient that did not. The patients who received liposomal bupivacaine also had a significant reduction in morphine milligram equivalents (MMEs).
Based on the investigators retrospective results, the investigators performed a power analysis which allowed for the development of this prospective randomized double blinded trial comparing liposomal bupivacaine plus plain bupivacaine vs. plain bupivacaine only in near equipotent doses. The investigators believe that this is a very important and unique trial to perform as it could change the way pain management is delivered in this patient population. Longer acting local anesthetic used for interscalene blocks may increase the number of patients who have tolerable pain and require less or no opioids. This could reduce or inevitably eliminate the unwanted effects of opioids (nausea, vomiting, constipation, urinary retention, opioid induced respiratory depression, dependency and addiction) and result in an improvement in the quality of recovery of patients undergoing total shoulder arthroplasties.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Liposomal Bupivacaine Group 10 mL (133 mg) Liposomal bupivacaine and 20 mL (50 mg) 0.25% bupivacaine and 6 mL of saline (183 mg) |
Drug: Liposomal bupivacaine
Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
Other Names:
|
| Other: Plain Bupivacaine Group 36 mL (180 mg) 0.5% bupivacaine |
Drug: Bupivacaine
Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- The difference in the proportion of patients with clinically significant tolerable pain scores [at Post-operative Day 1]
The investigators will collect the difference in the proportion of patients with clinically significant tolerable pain scores (defined as VAS ≤ 4) post-op Day One in those patients receiving an interscalene block with liposomal bupivacaine with plain bupivacaine vs. plain bupivacaine.
Secondary Outcome Measures
- The difference in the proportion of clinical tolerable pain scores in each group [on Post-operative Day 2, Day 3, Day 4, and Day 5]
The investigators will collect the difference in the proportion of clinical tolerable pain scores (defined as Visual Analogue Scale (VAS) ≤ 4) in each group.
- The difference in Visual Analogue Scale (VAS) pain scores (0 - 10) [Upon Post Anesthesia Care Unit (PACU) admission; Day 0; Post-operative Day 1, Day 2, Day 3, Day 4, and Day 5.]
The investigators will collect the difference in VAS pain scores (0 - 10) in each group. Subjects will rate their pain level on a scale of 0-10. Number "0" indicates no pain and number "10" indicates terrible pain.
- The difference in quality of recovery survey-15 responses [on Post-operative Day 1, Day 2, Day 3, Day 4 and Day 5.]
The investigators will collect the difference in quality of recovery survey-15 responses in each group. QoR15 survey has a scale of 0-10. Number "0" indicates none of the time and number "10" indicates all of the time.
- Opioid use in morphine milligram equivalents (MME) [on day of surgery; on Post-operative Day 1, Day 2, Day 3, Day 4, and Day 5]
The investigators will collect opioid use in morphine milligram equivalents data from the patients electronic medical record and via an electronic survey sent to patients.
- Use of non-opioid analgesics [on day of surgery; on Post-operative Day 1, Day 2, Day 3, Day 4, and Day 5]
The investigators will collect the use of non-opioid analgesics data from the patients electronic medical record and via an electronic survey sent to patients.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject ages 18-90 years old
-
Male or Female subjects
-
Weight ≥ 60 kg.
-
Must be able to consent in English
Exclusion Criteria:
-
Ages: <18 and >90
-
Weight < 60 kg
-
Multiple surgeries during one hospital stay
-
Emergency surgery
-
Allergy or any contraindication to local anesthetics used in trial.
-
Pregnancy
-
Contraindicated for use of liposomal bupivacaine
-
Severe liver/kidney disease
-
Defined as a diagnosis of end-stage renal disease (ESRD) defined as being on dialysis
-
Subject who received another local anesthetic block prior to the interscalene block.
-
Unable to consent in English
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | NorthShore University HealthSystem | Skokie | Illinois | United States | 60076 |
Sponsors and Collaborators
- Johnny K. Lee
- NorthShore University HealthSystem
Investigators
- Principal Investigator: Johnny K Lee, MD, NorthShore University HealthSystem
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EH23-069